A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Ce
A phase 2 trial of Cemiplimab in non-small-cell lung cancer and small-cell lung cancer, run by Regeneron Pharmaceuticals, active and no longer recruiting.
Overview
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC) is a phase 2 interventional study registered as NCT06465329 by Regeneron Pharmaceuticals, with 120 participants planned, started 2024-11-18 and due to reach its primary completion in 2027-05-20. Interventions recorded: Cemiplimab, Platinum-based chemotherapy, REGN7075. Conditions listed: Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small
Shares Cemiplimab, Regeneron, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers
Shares REGN7075, Cemiplimab, Regeneron.
- TrialA Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Shares REGN7075, Regeneron, Non-small-cell lung cancer.
- TrialA Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small
Shares Cemiplimab, Regeneron, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialNeoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients
Shares Cemiplimab, Regeneron, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialPhase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)
Shares Cemiplimab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult
Shares Cemiplimab, Regeneron, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemoth
Shares Cemiplimab, Regeneron, Small-cell lung cancer, Non-small-cell lung cancer.